A Retrospective Database Analysis of Anticholinergic Burden Among Older Patients With and Without Overactive Bladder in South Korea
In patients with OAB, 100-day cumulative anticholinergic cognitive burden score was 15 times higher than in patients without OAB, due to anticholinergic medications. In this study, mirabegron did not contribute to anticholinergic burden. As there are unwanted effects associated with this burden, clinicians should consider the anticholinergic burden of each patient when using pharmacotherapy to treat OAB.
Authors
- Chee Yoong Foo (ORCID: https://orcid.org/0000-0002-1833-4290)
- Kwang Jin Ko (ORCID: https://orcid.org/0000-0003-1085-1266)
- Kyu-Sung Lee
- Soyoung Kim (ORCID: https://orcid.org/0000-0002-8678-5341)
- Juhee Cho (ORCID: https://orcid.org/0000-0001-9081-0266)
- Farid Abdul Hadi
- Matthias Stoelzel (ORCID: https://orcid.org/0000-0002-2058-7385)
Institutions
- Astellas Pharma (Japan) (JP)
- Samsung Medical Center (KR)
- IQVIA (United Kingdom) (GB)
- Astellas Pharma (Germany) (DE)
- IQ Solutions (US)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- International Neurourology Journal
- Published
- 2025-09-26
- DOI
- https://doi.org/10.5213/inj.2550112.056
- Citations
- 2
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 3.67
Funders
- Astellas Pharma
- Samsung